Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases

Grant M. Fischer\textsuperscript{1,2}; Renato A. Guerrieri\textsuperscript{1,2}; Qianghua Hu\textsuperscript{1,2}; Aron Y. Joon\textsuperscript{1}; Swaminathan Kumar\textsuperscript{1,2}; Lauren E. Haydu\textsuperscript{1}; Jennifer L. McQuade\textsuperscript{2}; Y. N. Vashisht Gopal\textsuperscript{2,3}; Barbara Knighton\textsuperscript{1,2}; Wanleng Deng\textsuperscript{1,2}; Courtney W. Hudgens\textsuperscript{1,5}; Alexander J. Lazar\textsuperscript{1,5,6}; Michael T. Tetzlaff\textsuperscript{1,5}; and Michael A. Davies\textsuperscript{1,2,7}

\textsuperscript{1}Departments of Translational Molecular Pathology; \textsuperscript{2}Melanoma Medical Oncology; \textsuperscript{3}Biostatistics; \textsuperscript{4}Surgical Oncology; \textsuperscript{5}Pathology/Lab Medicine; \textsuperscript{6}Genomic Medicine; and \textsuperscript{7}Systems Biology – The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Corresponding Author:

Michael A. Davies

1515 Holcombe Blvd., Unit 0430
Houston, TX 77030
Phone: 713-792-3454
Fax: 713-745-1046
Email: mdavies@mdanderson.org

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Funding. GMF received research funding from the NIH National Center for Advancing Translational Sciences (TL1TR000369 and UL1TR000371) and The University of Texas MD Anderson Cancer Center (MD Anderson)/UTHealth Graduate School of Biomedical Sciences’ Caroline Ross Fellowship, Schissler Foundation Fellowship, and Presidents’ Research Scholarship. MAD is supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the NIH/NCI (2T32CA009666-21), the American Cancer Society and the Melanoma Research Alliance, the MD Anderson Multidisciplinary Research Program, Cancer Fighters of Houston, the Anne and John Mendelsohn Chair for Cancer Research, and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson. AJL is supported by the MD Anderson Melanoma Moon Shots Program and the NIH Melanoma SPORE (P50CA221703). JLM is supported by the Melanoma Research Alliance, an ASCO/CCF Career Development Award, Elkins Foundation, Rising Tide Foundation, Mark Foundation, and Seerave Foundation, an MD Anderson Melanoma SPORE Developmental Research Award (P50 CA093459), and an NIH T32 Training Grant Award (CA009666). YNVG is supported by a Melanoma Research Alliance Young Investigator Award (348483).

Conflicts of Interest. MAD has been a consultant to Roche/Genentech, Array, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex and Apexigen, and he has been the PI of research grants to MD Anderson by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, and Oncothryeon. JLM has been a consultant for Roche/Genentech, BMS, and Merck. MTT has been a consultant Novartis, Myriad Genetics, and Seattle Genetics. AJL has been a consultant for BMS, GSK/Novartis, Roche/Genentech/Ignyta, MedImmune/AstraZeneca, Bayer/Loxo, Merck, Guardant and ArcherDX.

Author Contributions. Concept and design: GMF, MAD; Acquisition of data: GMF, RAG, QH, AYJ, LEH, BK, CWH, AJL, MTT, MAD; Analysis and interpretation of data: GMF, AYJ, MAD; Writing, review, and/or revision of the manuscript: All authors; Study supervision: GMF, MAD.
ABSTRACT

Background: Recently, we showed that melanoma brain metastases (MBMs) are characterized by increased utilization of the oxidative phosphorylation (OXPHOS) metabolic pathway compared to melanoma extracranial metastases (ECMs). MBM growth was inhibited by a potent direct OXPHOS inhibitor, but observed toxicities support the need to identify alternative therapeutic strategies. Thus, we explored the features associated with OXPHOS to improve our understanding of the pathogenesis and potential therapeutic vulnerabilities of MBMs.

Methods: We applied an OXPHOS gene signature to our cohort of surgically resected MBMs that had undergone RNA-sequencing (RNA-seq) (n=88). Clustering by curated gene sets identified MBMs with significant enrichment (High-OXPHOS; n=21) and depletion (Low-OXPHOS; n=25) of OXPHOS genes. Clinical data, RNA-seq analysis, and immunohistochemistry were utilized to identify significant clinical, molecular, metabolic, and immune associations with OXPHOS in MBMs. Preclinical models were used to further compare melanomas with High- and Low-OXPHOS and for functional validation.

Results: High-OXPHOS MBMs were associated with shorter survival from craniotomy compared to Low-OXPHOS MBMs. High-OXPHOS MBMs exhibited an increase in glutamine metabolism, and treatment with the glutaminase inhibitor CB839 improved survival in mice with MAPKi-resistant, High-OXPHOS intracranial xenografts. High-OXPHOS MBMs also exhibited a transcriptional signature of deficient immune activation, which was reversed in B16-F10 intracranial tumors with metformin treatment, an OXPHOS inhibitor.

Conclusions: OXPHOS is associated with distinct clinical, molecular, metabolic and immune phenotypes in MBMs. These associations suggest rational therapeutic strategies for further testing to improve outcomes in MBM patients.

Keywords: melanoma, brain metastases, oxidative phosphorylation, targeted therapy, immune therapy
KEY POINTS

1. OXPHOS correlates with shorter survival in melanoma brain metastasis (MBM) patients.
2. OXPHOS associates with distinct molecular, metabolic and immune features in MBMs.
3. Targeting OXPHOS-associated features could improve treatments for MBMs.

IMPORTANCE OF THE STUDY

We have recently demonstrated that increased oxidative phosphorylation (OXPHOS) is a hallmark and functional dependency of melanoma brain metastases (MBMs). However, little is known about the contribution of OXPHOS to the pathogenesis of MBMs, which could inform the rational development of new therapeutic strategies for affected patients. As OXPHOS levels are heterogeneous among MBMs, we compared High- and Low-OXPHOS tumors to identify features significantly associated with this metabolic phenotype. Our results show that High-OXPHOS in MBMs is associated with shorter survival, increased mTOR activation, increased utilization of glutamine metabolism, and an immunosuppressed tumor microenvironment. Our studies in preclinical models support the functional nature and importance of these metabolic and immune associations. Together the results provide new information about the pathogenesis of OXPHOS in MBMs, and they suggest potential new therapeutic strategies for these aggressive tumors.
INTRODUCTION

Melanoma is the most aggressive of the common forms of skin cancer, and has among the highest risk of brain metastasis among all solid tumors.\(^1\)\(^2\) Despite many advances in systemic treatments, brain metastases remain a critical challenge to overcome to further improve patient outcomes. For example, the COMBI-MB trial showed that although the FDA-approved targeted therapy regimen of dabrafenib and trametinib achieves intracranial responses in \(\sim 60\%\) of patients with melanoma brain metastases (MBMs), the duration of response was \(\sim 50\%\) shorter than that achieved in melanoma extracranial metastases (ECMs).\(^3\) Further, the FDA-approved anti-PD1 antibodies pembrolizumab and nivolumab achieve clinical responses in only \(\sim 20\%\) of patients with MBMs, which is much lower than the response rate (\(\sim 40\%\)) in patients without central nervous system (CNS) involvement.\(^4\)\(^5\) A more promising intracranial benefit rate (58.4%) was achieved with ipilimumab and nivolumab combination immunotherapy in patients with asymptomatic MBMs, but the intracranial benefit rate was only 22.2% in patients with symptomatic tumors.\(^6\)\(^7\) Thus, there remains an unmet need to develop new approaches to more effectively prevent and/or treat MBMs.

We recently reported the first RNA-sequencing (RNA-seq) analysis of melanoma patients that underwent surgical removal of both MBMs and ECMs. This RNA-seq analysis showed that MBMs were characterized by increased expression of genes involved in the oxidative phosphorylation (OXPHOS) metabolic pathway, and decreased immune cell infiltrates, compared to patient-matched ECMs.\(^8\) We and others have previously shown that OXPHOS mediates \textit{de novo} and acquired resistance to FDA-approved MAPK pathway inhibitors.\(^9\)\(^11\) More recently, OXPHOS has also been implicated in resistance to anti-PD1 immunotherapy.\(^12\)\(^13\) Importantly, we showed that treatment with IACS-010759, a potent direct OXPHOS inhibitor, significantly improved the survival of mice with intracranial melanoma xenografts, supporting the functional significance of OXPHOS in MBMs.\(^8\) However, IACS-010759 has been associated with significant toxicity in preclinical models and in early-phase clinical trials.\(^14\)\(^15\) Thus, there is a need to identify alternative strategies to overcome this metabolic pathway’s negative effects.
Here we have used our unique cohort of characterized MBMs, and melanoma preclinical models, to identify clinical, molecular, immune, and metabolic features that are associated with OXPHOS. These studies provide new insights into the pathogenesis of OXPHOS in MBMs. Our results also suggest potential new therapeutic strategies for this common and deadly manifestation of metastatic melanoma.

MATERIALS & METHODS

Cell Lines

All cell lines were grown at 37°C under 5% CO₂. Luciferase-tagged A375, MEL624, and A375-R1 cells were grown in RPMI-1640 media supplemented with glutamine and heat-inactivated 5% fetal bovine serum (FBS) (Gibco). Luciferase-tagged B16-F10 cells [developed and provided by Dr. Willem Overwijk, MD Anderson] were grown in RPMI-1640 media supplemented with glutamine and 10% heat-inactivated FBS. Identity of the human cell lines was verified by short-tandem repeat (STR) fingerprinting at least every 6 months. All cell lines were confirmed negative for mycoplasma prior to the study using the MycoAlert Mycoplasma Detection Kit (Lonza) according to the manufacturer’s specifications. Species, mutations, and OXPHOS status of the cell lines are presented in Table S1.

Compounds

The following compounds were acquired: metformin (Cayman Chemical), isotype rat IgG control antibody (BioXCell, Clone: 2A3, #BE0089), anti-mouse PD1 antibody (BioXCell, Clone: RMP1-14, #BE0146), and AZD2014 (Selleck Chemical), and CB839 (Selleck Chemical). Compounds were formulated as previously described.
Mice

All mouse experiments were approved by the Institutional Animal Care and Use Committee. Female C57BL/6 and CD-1 nude mice were purchased from the Jackson Laboratory and Charles River Laboratory, respectively. Experiments using C57BL/6 and CD-1 nude mice at 8 weeks of age, housed in specific pathogen-free conditions, were performed at the MD Anderson South Campus Animal Vivarium.

**Stereotaxic intracranial injection.** Intracranial (ICr) tumors were established by direct injection, and monitored by bioluminescence imaging (BLI), in C57BL/6 mice (B16-F10) or CD-1 nude mice (A375, A375-R1, and MEL624) as previously described. Harvested tumors were washed briefly in ice-cold normal saline and either flash frozen in liquid nitrogen or fixed in formalin overnight, then dehydrated in 70% ethyl alcohol, and paraffin embedded.

**RNA-sequencing (RNA-seq) and Whole Exome Sequencing (WES) Analyses**

Raw counts and WES BAM files were acquired, and the OXPHOS-Index (OP-Index) was derived, as previously described. Comparisons of interest were performed using functions from the `edgeR` and `limma/voom` Bioconductor packages in R (v3.6.1). ssGSEA was conducted on TMM-normalized, voom-transformed log2-(CPM+0.5) expression matrices using the GenePattern module `ssGSEAProjection` (v9.0.10) with default settings to generate enrichment scores for the 8 OXPHOS-related gene sets listed in Table S2. Values from the 8 components of the OP-Indices of MBMs were median centered. Hierarchical clustering was conducted with distances calculated using Euclidean correlation metrics and clusters joined using complete linkage. Preranked GSEA (GSEA-P) was performed as previously described. CIBERSORT was run in “absolute mode” to estimate intratumoral immune cell populations from linear RPKM values, as previously described. Values were log2-transformed and median-centered for heatmap generation. All heatmaps were generated via ClustVis (https://biit.cs.ut.ee/clustvis/). MuTect 1.1.4 was used to detect potential single-nucleotide variations for samples with available WES data. In addition to the build-in filter we included variants
with allele frequency in tumor DNA ≥2% and allele frequency in germline DNA ≤ 2%, as well as total read number in tumor > 20 and total read number in normal tissue > 10.

**Targeted Metabolomics**

Mice bearing ICr A375 and A375-R1 tumors were euthanized once moribund. Harvested tumors were frozen in liquid nitrogen and submitted to the Baylor College of Medicine Metabolomics Core. Sample preparation and data acquisition for 46 metabolites (glycolytic/TCA cycle intermediates, amino acids, fatty acids, NADH, and ATP) are previously described. Normalized data was log2-transformed. For every metabolite in the normalized dataset, paired Student’s t-tests were conducted to compare expression levels between groups. Differential metabolites were identified by adjusting the p-values for multiple testing at a False Discovery Rate (FDR) threshold of <0.25, as previously described. All metabolites significantly upregulated in A375-R1 ICr xenografts (log2FC>0 and FDR q-val<0.25) were uploaded into MetaboAnalyst 4.0 (http://www.metaboanalyst.ca/). The Pathway Analysis tool set to default settings was used to perform overrepresentation analysis (ORA) of the significantly upregulated metabolites, as previously described.

**Therapeutic Studies**

Mice were weighed every 2 days and were euthanized if 20% weight loss occurred, or if mice were moribund or displaying neurological symptoms (ataxia, seizures, circling behavior, paralysis, or cranial doming). Treatments were designed to end 42 days after randomization unless otherwise specified. 

**AZD2014 efficacy analysis.** 1x10³ luciferase-tagged A375-R1 cells suspended in Hank’s Buffered Saline Solution (HBSS; Corning, Inc.) were directly implanted in the brain parenchyma of CD-1 nude mice. After 7 days, tumor uptake was confirmed via BLI and mice were randomized into 2 treatment arms: vehicle or AZD2014 (20 mg/kg p.o. once daily).
AZD2014 pharmacodynamics (PD) analysis. CD-1 nude mice bearing ICr A375-R1 xenograft tumors were treated with vehicle or AZD2014 (20 mg/kg p.o. once daily). On day 7, mice were given one final treatment. Three hours after this treatment, tumors were harvested and fixed in 10% formalin. FFPE slides of these tumors were generated and probed for P-S6 (marker of mTOR pathway activation).

Metformin+anti-PD1. 5x10³ luciferase-tagged B16-F10 cells suspended in HBSS were directly implanted in the brain parenchyma of C57BL/6 mice. After 5 days, tumor uptake was confirmed via BLI and mice were randomized into 4 treatment arms: isotype antibody (ab) control (200 µg i.p. 3x/week) + PBS (10 µl/g body weight i.p. every other day); anti-PD1 ab (200 µg i.p. 3x/week) + PBS (10 µl/g body weight i.p. every other day); isotype ab control (200 µg i.p. 3x/week) + metformin (50 mg/kg i.p. every other day); and anti-PD1 ab (200 µg i.p. 3x/week) + metformin (50 mg/kg i.p. every other day).

CB839 monotherapy. Cell proliferation inhibition was determined using Cell Titer Blue (Promega), as previously described. 9 1x10³ luciferase-tagged A375-R1 and 1x10⁴ MEL624 cells suspended in HBSS were directly implanted in the brain parenchyma of CD-1 nude mice. After 7 days, tumor uptake was confirmed via BLI, and mice were randomized to vehicle and CB839 (200 mg/kg p.o. twice daily) treatment groups.

qRT-PCR Analysis

RNA extraction and cDNA synthesis. The Roche High Pure miRNA kit was used according to manufacturer’s specifications for RNA extraction from B16-F10 ICr xenografts extracted and frozen after 96 hours of treatment with PBS (10 µ/g body weight i.p. every other day) or metformin (50 mg/kg i.p. every other day). 1000 ng of RNA was used to synthesize the first strand of cDNA using the High Capacity cDNA Archive kit (Applied Biosystems) following standard ABI Protocol.
**qRT-PCR.** Inventoried TaqMan assays were purchased from Life Technologies [Mm00443258_m1 (**Tnf**), Mm00812512_m1 (**Prf1**), Mm01168134_m1 (**Ifng**), Mm00442837_m1 (**Gzmb**), Mm01182107_g1 (**Cd8a**), Mm00445235_m1 (**Cxcl10**), Mm00434946_m1 (**Cxcl9**), Mm00492586_m1 (**Ido1**), Mm00439531_m1 (**Stat1**)]. All qRT-PCR reactions were performed using the 7900HT Fast Real-Time PCR system and Taqman gene expression master mix (Applied Biosystems) with a standard cycling program of 40 cycles at 95 °C for 15 s and at 60 °C for 1 min. All reactions were run in triplicate and normalized to human **18S** (Hs99999901_s1). Data was analyzed using the 2^ΔΔCT method.

**Bioenergetics Stress Test**

A Seahorse XFe96 Bioanalyzer (Agilent) was used to acquire oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) values as previously described. Data was normalized against cell numbers.

**Immunohistochemistry (IHC)**

All IHC studies were performed on 5 µm FFPE sections using a Leica BOND RXm autostainer. Slides were stained with antibodies targeting human P-S6 (Cell Signaling #4858, 1:100) and P-PRAS40 (Cell Signaling #13175, 1:200) using a modified version of either the standard Leica Bond DAB “F” or red “J” IHC protocols. Slides were scored by a board-certified pathologist and given an H-score based on percentage and intensity of positivity. CD3, CD8, PAX5, and PTEN staining and analyses were performed as previously described.8

**Statistical Analyses**

Overall survival (OS) was defined as the time interval from date of craniotomy (clinical samples) or treatment initiation (mouse studies) to censoring or date of death from any cause. Survival duration was analyzed by the Kaplan-Meier method. Survival curves were drawn in Prism 8.0
(GraphPad Software, La Jolla, California). Hazard ratios and significance were calculated via the Mantel-Haenszel test and log-rank test, respectively, in Prism 8.0 (GraphPad Software, La Jolla, California). Additional data analyses and representations were performed either with R (v3.6.1), Microsoft Excel 2013, or Prism 8.0 (GraphPad Software, La Jolla, California). Comparison of continuous variables between two groups was performed by unpaired or paired Student’s t-test. The Pearson correlation coefficient was calculated to assess correlation between continuous variables. To control for multiple hypothesis testing, we applied the Benjamini-Hochberg method. Lastly, all statistical significance testing was two-sided with a Type-I error rate of 0.05 except where specifically noted in relevant Figure legends.

RESULTS

Heterogeneity and Clinical Association of OXPHOS in MBMs

In order to characterize the heterogeneity of OXPHOS among MBMs, we calculated the OXPHOS-Index (OP-Index) for each tumor in our previously described cohort of 88 MBMs with available RNA-seq data. Hierarchical clustering identified three clusters, which we termed “High-OXPHOS,” “Intermediate-OXPHOS”, and “Low-OXPHOS” (Fig. 1A). Pre-ranked Gene Set Enrichment Analysis (GSEA-P) confirmed that the KEGG OXPHOS gene set was significantly enriched (FDR q-val < 0.0001) in High- vs. Low-OXPHOS MBMs (Fig. 1B).

We tested whether OXPHOS status was associated with clinical features of MBM patients. We compared the outcome of High-OXPHOS vs. Low-OXPHOS MBMs for this and future analyses, as the difference in gene expression was most significant for these groups (Fig. 1B and Fig. S1A-B). Supporting the clinical significance of the observed heterogeneity of OXPHOS amongst MBMs, patients with Low-OXPHOS MBMs had improved OS from craniotomy vs. patients with High-OXPHOS (HR 0.393, 95% CI 0.187-0.830, p=0.0143) (Fig. 1C). In contrast to the association with clinical outcomes, review of clinical features showed that OXPHOS status was not associated
significantly with age, gender, body mass index (BMI), or history of prior radiation therapy (XRT) (Fig. 1D-G). There was also no significant association for OXPHOS status with history of prior systemic therapy (p=0.23).

Molecular Associations of High-OXPHOS in MBMs

As multiple pathways have been implicated in melanoma progression and therapeutic resistance, we next analyzed MBMs for molecular associations with OXPHOS. As anticipated, High-OXPHOS MBMs expressed higher levels of PGC1α, a transcriptional co-factor that is a critical regulator of many OXPHOS-related genes in melanoma,\textsuperscript{9,11,23} compared to Low-OXPHOS MBMs (p.adj=0.0188) (Fig. 2A). High-OXPHOS MBMs also had higher expression of MITF, a lineage-specific transcription factor that regulates PGC1α in melanoma (p.adj=0.0169) (Fig. 2A).\textsuperscript{9,11,23} Previously, we observed in human melanoma cell lines that MITF activity, and thus PGC1α expression, are regulated in melanoma by mTOR.\textsuperscript{9} Consistent with that result, GSEA-P analysis of High- versus Low-OXPHOS MBMs demonstrated significant enrichment (FDR q-val<0.0001) of genes regulated by the mTORC1 signaling pathway in High-OXPHOS tumors (Fig. 2B). As previous protein-based studies of MBMs by our group and others identified increased activation of the PI3K-AKT pathway in MBMs,\textsuperscript{24,25} we further evaluated the molecular associations of OXPHOS status in MBMs by performing IHC for PTEN (complete loss promotes PI3K-AKT pathway activity), P-PRAS40 (marker of AKT activity), and P-S6 (marker of mTORC1 activity). While we detected no significant difference in PTEN loss (p=0.7756) or P-PRAS40 expression (p=0.4339) (Fig. 2C-D), P-S6 expression was significantly increased (p=0.0027) in High- vs. Low-OXPHOS MBMs, suggesting association with mTOR activity, but not PI3K/AKT (Fig. 2E-F). We did not detect any significant difference in the prevalence of activating \textit{BRAF} mutations, nor in the mutation rate of 74 therapeutically targetable genes, between tumors with High- vs. Low-OXPHOS (Table S3).\textsuperscript{26}

\textit{Based on the findings implicating increased mTOR signaling in High-OXPHOS MBMs, we evaluated the clinical efficacy of AZD2014, a mTORC1/2 inhibitor previously shown to completely ablate mTOR signaling and synergize with MEKi in subcutaneous High-OXPHOS melanoma...}
Mice bearing intracranial xenografts of the High-OXPHOS A375-R1 cell line were randomized to treatment with AZD2014 (20 mg/kg p.o. once daily) or vehicle control. AZD2014 failed to improve OS relative to vehicle controls (Fig. S2A). Because AZD2014 works most effectively when combined with MEKi, we investigated if the lack of efficacy for A375-R1 intracranial xenografts was due to insufficient target inhibition or because this drug is simply inadequate as a single-agent strategy. Interestingly, 7 days of treatment with AZD2014 did not suppress P-S6 staining compared to vehicle controls (p=0.8623), indicating that the drug failed to inhibit its target (Fig. S2B-C) in the intracranial xenografts, thus making it a poor candidate for further MBM therapeutics studies.

**Increased Glutamine Metabolism in High-OXPHOS MBMs**

Oxidative phosphorylation interacts with numerous other metabolic pathways. Thus, to better understand the metabolic features of High-OXPHOS MBMs, we selected 70 MSigDB KEGG metabolism-specific gene sets (Table S4) and performed GSEA-P on the High- vs. Low-OXPHOS MBMs. As expected, the KEGG OXPHOS gene set was the most enriched pathway in the High-OXPHOS MBMs (FDR q-val<0.0001) (Fig. 3A). Interestingly, the next most enriched pathways included purine synthesis, pyrimidine synthesis, and aminoacyl tRNA biosynthesis (Fig. 3A). Enrichment of these nucleic acid synthesis and protein synthesis pathways suggests increased growth potential in High-OXPHOS MBMs. Importantly, all of these pathways require glutamine, which represents a potential therapeutic target.

Direct metabolite analysis was not feasible on the clinical samples, as they were all FFPE. Thus, we performed liquid chromatography-mass spectrometry (LC-MS) analysis on fresh A375 (BRAF mutant human melanoma, Low-OXPHOS) and A375-R1 (A375 subclone with acquired resistance to MAPKi and High-OXPHOS) intracranial xenografts to further explore the metabolic features of High- and Low-OXPHOS MBMs. As expected, A375-R1 MBMs had significantly higher concentrations of the TCA cycle metabolites malate and fumarate, and lower concentrations of the glycolytic metabolites phosphoenolpyruvate and 3-phosphoglycerate, versus A375 (Fig. 3B). A375-R1 MBMs also had significantly increased concentrations of glutamic acid and asparagine, consistent
with increased glutaminolysis (Fig. 3B). Pathway analysis of differentially expressed metabolites (DEMs) identified significant enrichment (FDR q-val<0.05) of glutamate metabolism and pathways that require nitrogen from glutamine (Fig. 3C).

Based on these results, we evaluated the effects of CB839, a small molecule glutaminase inhibitor currently being used in clinical trials, on Low-OXPHOS A375 and High-OXPHOS A375-R1 cells in vitro. CB839 significantly inhibited OCR in A375-R1 cells, but not in A375 cells (Fig. 3D-E). CB839 treatment did not inhibit ECAR in the A375-R1, indicating that glycolysis did not depend on glutamine in the cell line (Fig. S3). A375-R1 cells were also more sensitive to growth inhibition (IC50 182 nM) by CB839 than A375 cells (IC50 437 nM) (Fig. 3F). CB389 treatment significantly improved the OS of mice with A375-R1 intracranial xenografts (median OS 13 vs. 5 days; p=0.0292) (Fig. 3G). CB839 also improved OS of mice with intracranial xenografts of MEL624, a BRAF-mutant human melanoma cell line with High-OXPHOS and de novo resistance to MAPKβ (median OS 31 vs. 16 days; p=0.0266) (Fig. 3H).9,15 No significant weight loss or toxicity was observed with CB839 treatment (Fig. S4), consistent with the favorable safety profile observed in patients.28

**Immune Features Associated with OXPHOS in MBMs**

In addition to increased OXPHOS, our previous analysis identified decreased immune cell infiltrates in MBMs compared to ECMs.8 Thus, we assessed if there are significant immunologic differences between High- and Low-OXPHOS MBMs. High-OXPHOS MBMs had significantly lower ImmuneScores, which is a metric calculated from the expression of 141 immune-related genes from numerous different immune cell subpopulations, compared to Low-OXPHOS MBMs (p=0.0034) (Fig. S5). Interestingly, CIBERSORT analysis of RNA-seq data identified no significant differences in any of 22 immune cell subpopulations (Fig. 4A). Consistent with the CIBERSORT analysis, IHC staining showed no significant differences in CD3+ or CD8+ cells (T-cell markers) (Fig. 4B-C) or PAX5+ cells (B-cell marker) (Fig. 4D) between High- and Low-OXPHOS MBMs. While we did not observe significant differences in any of the immune cell subpopulation infiltrating the tumors, High-OXPHOS MBMs were characterized by significantly lower expression (p=0.0263) of a
6-gene IFNγ mRNA signature that correlates with improved responsiveness to anti-PD1 immunotherapy. Further, High-OXPHOS MBMs express significantly lower T cell–inflamed gene expression profile (GEP) (p=0.0087) than Low-OXPHOS MBMs (Fig. 4F). This larger signature, which also predicts response to anti-PD1, features IFNγ–responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance.

In previous experiments using subcutaneous B16-F10 murine melanoma tumors, treatment with a low-dose metformin regimen inhibited OXPHOS exclusively in tumor cells and improved responsiveness to anti-PD1. To determine if metformin can also improve the immune microenvironment of MBMs, mice with intracranial luciferase-tagged B16-F10 tumors were treated with the low-dose metformin regimen (50 mg/kg i.p. every other day) or PBS for 96 hours, and then were euthanized. qRT-PCR was performed on RNA isolated from the MBMs for a 5-gene signature indicative of activated CD8+ cytotoxic T cells, and 5 genes from the aforementioned 6-gene IFNγ mRNA signature (HLA-DRA is only found in humans and was therefore excluded). Metformin treatment significantly increased the expression of all 11 genes (p<0.05 – p<0.0001), consistent with improved immune functionality in the tumor microenvironment (TME) (Fig. 5A-B). Additional mice were implanted intracranially with luciferase-tagged B16-F10 to test the therapeutic effects of metformin. After confirming tumor uptake, mice were treated with isotype control antibody, anti-PD1, metformin, or anti-PD1 with metformin. Only treatment with anti-PD1 and metformin improved OS versus control (median 18 vs. 10 days; p=0.0127) (Fig. 5C). Mice treated with the combination also had significantly improved OS compared to metformin alone (median 18 vs. 12 days; p=0.0262). While the combination quantitatively improved OS versus anti-PD1 alone, the result was not statistically significant (median OS 18 vs. 11 days, p=0.1972).

**DISCUSSION**

Previous studies by our group and others have implicated increased OXPHOS as a predictor of poor clinical outcomes and as a hallmark of brain metastases in patients with metastatic melanoma. Thus, there is a critical need to improve our understanding of the pathogenesis of this metabolic phenotype, and to develop rational, new therapeutic approaches to combat it. Our analyses of the unique cohort of surgically resected, molecularly characterized MBMs has demonstrated that
OXPHOS is associated with significantly shorter OS, increased glutaminolysis, and impaired immune function. These results provide new insights into the pathogenesis of brain metastases and OXPHOS in this disease. Further, our functional studies support that targeting pathways and phenotypes associated with OXPHOS may be beneficial for MBMs.

The observed positive associations with PGC1α, MITF, and mTOR activity with OXPHOS levels in MBMs are consistent with our previous studies performed in melanoma cell lines. Notably, we previously showed that High-OXPHOS cell lines and xenografts were sensitive to combined treatment with the mTORC1/2i AZD2014 plus the MEKi AZD6244. However, here our pilot experiments showed that AZD2014 did not inhibit mTOR in intracranial xenografts, despite using a dose equivalent to twice the maximum tolerated dose in humans. Additional investigations are needed to evaluate additional dosing schedules with AZD2014 and/or other mTORC1/2 inhibitors as a therapeutic agents, but may be challenging to translate due to their toxicities. Of note, our recent work showed that treatment with the direct OXPHOS inhibitor IACS-010759 could inhibit mTOR signaling, suggesting a feedback circuit between these signaling and metabolic pathways.

While we previously showed that IACS-010759 had single-agent activity in MBM models, results from phase I clinical testing and preclinical studies suggest that the toxicities observed with this agent may make clinical development challenging, particularly as a combinatorial strategy. Thus, there is a strong rationale to identify other targetable dependencies of High-OXPHOS MBMs. Interestingly, our analysis of clinical and preclinical samples demonstrates utilization of, and dependence upon, glutamine metabolism in High-OXPHOS MBMs. Our RNA-based studies demonstrated increased activity of multiple glutamine-dependent metabolic pathways in clinical samples, and direct metabolite analysis of High- and Low-OXPHOS preclinical MBM models confirmed increased glutamine metabolism in High-OXPHOS MBMs. These results are consistent with work by Baenke et al., which showed that melanomas with acquired resistance to BRAF inhibitors with High-OXPHOS switched from glucose to glutamine as their primary energy source. Excitingly, CB839, a novel small molecule glutaminase inhibitor currently being used in multiple clinical trials, improved survival as a single-agent in two different models of High-OXPHOS, MAPKi-resistant MBMs (A375-R1 and MEL624). The favorable toxicity profile of CB839 supports
the feasibility of evaluating combinatorial strategies, in addition to single-agent activity. Notably, clinical trials conducted to date in melanoma with CB839 have excluded patients with active CNS disease, though our results suggest this agent could particularly benefit patients with MBMs. Indeed, our results here and previously strongly support that both preclinical and clinical investigations of strategies targeting OXPHOS and associated pathways should include evaluation of brain metastases. Additional studies are also needed to further characterize the effects of glutaminase inhibition in melanoma, including further characterization of metabolic effects and the impact on MBMs with relatively Low OXPHOS.

Finally, our analyses demonstrate that OXPHOS is associated with features consistent with functional immunosuppression in MBMs, including significantly decreased expression of gene signatures that predict response to anti-PD1 immunotherapy. These findings are consistent with the decreased responsiveness observed with pembrolizumab and with nivolumab in MBM patients. The OXPHOS-associated decrease in immune activation without changes in the degree of immune cell subpopulation infiltration is also consistent with recent analyses of biopsies of ECMs with increased OXPHOS from metastatic melanoma patients receiving anti-PD1 treatment. Notably, in preclinical models, it was previously shown that OXPHOS inhibition can enhance response to anti-PD1 immunotherapy in subcutaneous xenografts, which we also observed in our experiments with B16-F10 MBMs. Together our results are consistent with growing data implicating aberrant metabolism in resistance to immunotherapy in melanoma, and they are the first to directly implicate OXPHOS as a mediator of immunosuppression in MBMs. Overall the results strongly support the rationale to further explore strategies combining metabolic inhibitors with anti-PD1, including in additional murine and/or humanized MBM mouse models. Furthermore, the results highlight the critical need to include, not exclude, patients with brain metastases in such clinical trials.
REFERENCES

1. Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. *CA: A Cancer Journal for Clinicians*. 2016:n/a-n/a.

2. Cohen JV, Tawbi H, Margolin KA, et al. Melanoma Central Nervous System Metastases: Current Approaches, Challenges, and Opportunities. *Pigment Cell & Melanoma Research*. 2016; 29(6):627-642.

3. Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. *The Lancet Oncology*. 2017; 18(7):863-873.

4. Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *The Lancet Oncology*. 2018; 19(5):672-681.

5. Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. *The Lancet Oncology*. 2016; 17(7):976-983.

6. Tawbi H, Forsyth PA, Hodi FS, et al. Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate2014). *J Clin Oncol*. 2019; 37(Suppl):9501.

7. Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. *New England Journal of Medicine*. 2018; 379(8):722-730.
8. Fischer GM, Jalali A, Kircher DA, et al. Molecular profiling reveals unique immune and metabolic feature of melanoma brain metastases. *Cancer Discov.* 2019; 9(5):628-645.

9. Gopal YNV, Rizos H, Chen G, et al. Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma. *Cancer Research.* 2014; 74(23):7037-7047.

10. Roesch A, Vultur A, Bogeski I, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. *Cancer Cell.* 2013; 23(6):811-825.

11. Haq R, Shoag J, Andreu-Perez P, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. *Cancer Cell.* 2013; 23(3):302-315.

12. Najjar YG, Menk AV, Sander C, et al. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. *JCI Insight.* 2019; 4(5).

13. Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM. Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. *Cancer Immunol Res.* 2017; 5(1):9-16.

14. Yap TA, Rodon Ahnert J, Piha-Paul SA, et al. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. *Journal of Clinical Oncology.* 2019; 37(15_suppl):3014-3014.

15. Vashisht Gopal YN, Gammon S, Prasad R, et al. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. *Clinical Cancer Research.* 2019; 25(21):6429-6442.
16. Davies MA, Stemke-Hale K, Lin E, et al. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. *Clin Cancer Res.* 2009; 15(24):7538-7546.

17. Gross MI, Demo SD, Dennison JB, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. *Mol Cancer Ther.* 2014; 13(4):890-901.

18. Ozaki T, James CD. Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. *J Vis Exp.* 2010; 41:1986.

19. Law CW, Alhamdoosh M, Su S, Smyth GK, Ritchie ME. RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR. *F1000Research.* 2016; 5:1408.

20. Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. *Methods in molecular biology.* 2018; 1711:243-259.

21. Putluri N, Shojaie A, Vasu VT, et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. *Cancer Res.* 2011; 71(24):7376-7386.

22. Chong J, Soufan O, Li C, et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. *Nucleic Acids Res.* 2018; 46(W1):W486-W494.

23. Vazquez F, Lim JH, Chim H, et al. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. *Cancer Cell.* 2013; 23(3):287-301.
24. Chen G, Chakravarti N, Aardalen K, et al. Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. *Clinical Cancer Research.* 2014; 20(21):5337-5346.

25. Niessner H, Forschner A, Klumpp B, et al. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. *Cancer Medicine.* 2013; 2(1):76-85.

26. Chen K, Meric-Bernstam F, Zhao H, et al. Clinical actionability enhanced through deep targeted sequencing of solid tumors. *Clinical Chemistry.* 2015; 61(3):544-553.

27. Baenke F, Chaneton B, Smith M, et al. Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. *Molecular Oncology.* 2016; 10(1):73-84.

28. Meric-Bernstam F, Gordon M, Tykodi SS, et al. CX-839-004: a phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma (MEL), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC). *J Immunother Cancer.* 2017; 5(Suppl 2):9.

29. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. *J Clin Invest.* 2017; 127(8):2930-2940.

30. Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HL. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. *Sci Transl Med.* 2018; 10(471).
31. Zhang G, Frederick DT, Wu L, et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. *The Journal of Clinical Investigation.* 2016; 126(5):1834-1856.

32. Fantus D, Dai H, Ono Y, et al. Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection. *Transplantation.* 2017; 101(12):2830-2840.
FIGURE LEGENDS

Figure 1. Identification of High-OXPHOS and Low-OXPHOS melanoma brain metastases. (A) Hierarchical clustering of the OXPHOS-Indices from 88 MBMs with available RNA-seq data resulted in the formation of 3 clusters: MBMs with significant enrichment (High-OXPHOS; n=21); depletion (Low-OXPHOS; n=25); or intermediate (Intermediate-OXPHOS; n=42) OXPHOS gene set enrichment. Results are represented as a heatmap of median-centered values from each of the 8 components of the OXPHOS-Index. (B) GSEA-P confirming enrichment of OXPHOS in MBMs identified as High-OXPHOS versus Low-OXPHOS. (C) Kaplan-Meier analysis of OS from craniotomy for patients with High-OXPHOS versus patients with Low-OXPHOS MBMs. Hazard ratio determined via Mantel-Haenszel test and significance by log-rank test. (D-G) Comparison of clinical variables between patients with High- and Low-OXPHOS MBMs, including mean age, gender, mean body mass index (BMI), and frequency of previous radiation XRT). Significance was determined for age and BMI via two-sided Student’s t-test; gender and frequency of prior XRT were compared via two-sided Fisher’s exact test.

Figure 2. Molecular associations of OXPHOS in melanoma brain metastases. (A) Gene expression analysis of PGC1α and MITF (by RNAseq) in High-(Red) versus Low-OXPHOS (Blue) MBMs. Each plot is a simple box and whisker plot. Median values (lines) and interquartile range (whiskers) are indicated. Adjusted p values calculated via generalized linear model analysis are listed. (B) Cumulative GSEA-P enrichment plot demonstrating significant enrichment or depletion (FDR q-val<0.0001) of MSigDB Hallmarks gene sets in High-OXPHOS vs. Low-OXPHOS MBMS identified via clustering methods. The 10 most up-regulated gene sets are shown in red. All significantly down-regulated gene sets are shown in blue. The normalized enrichment score (NES) forms the x-axis. (C) Comparison of the prevalence of complete PTEN loss by IHC for High-OXPHOS and Low-OXPHOS MBMs. Y-axis represents the frequency (%) of MBMs with complete absence of PTEN expression. Significance determined via two-sided Fisher’s exact test. (D) Comparison of P-PRAS40 IHC expression by H-scores for High-OXPHOS versus Low-OXPHOS MBMs. Lines represent mean ±
S.D.; each dot represents a single tumor. Significance determined via two-sided Student’s t-test. (E) Comparison of P-S6 IHC expression by H-scores for High-OXPHOS versus Low-OXPHOS MBMs. (F) Representative P-S6 staining in High- and Low-OXPHOS MBMs. Samples selected reflect the median H-scores in the High- (median = 35) and Low- (median = 10) OXPHOS MBMs. Tumor cells are present throughout the entirety of both samples.

Figure 3. Metabolic profiling of High-OXPHOS MBMs identifies glutamine metabolism as a therapeutic target. (A) Cumulative GSEA-P enrichment plot demonstrating significant enrichment or depletion (FDR q-val<0.0001) of KEGG metabolism gene sets in High-OXPHOS versus Low-OXPHOS MBMS. Enriched gene sets are shown in red. No depleted gene sets met the criteria for significance. X-axis shows the normalized enrichment score (NES) for each pathway. (B) Differentially expressed metabolites (FDR q-val<0.25) between A375 (Low-OXPHOS; n=5) and A375-R1 (High-OXPHOS; n=4) human melanoma intracranial xenografts, as determined by liquid chromatography mass spectrometry (LC-MS). Heatmap shows median-centered log2-transformed concentrations of these metabolites. (C) Pathway analysis of metabolites significantly upregulated (log2FC>0 and FDR q-val<0.25) in A375-R1 versus A375 intracranial xenografts. All pathways listed are significantly enriched in A375-R1 versus A375 (FDR q-val < 0.05). (D-E) Seahorse mitochondrial stress test results for A375 and A375-R1 cells treated for 12 hours with vehicle or 100 nM of CB839 in vitro. The figures show basal, oligomycin-inhibited (“O”), FCCP-activated (“F”) and Antimycin/Rotenone inhibited (“A&R”) oxygen consumption rate (OCR) levels. Data is representative of quadruplicates and S.D. (F) Cell proliferation inhibition of A375 and A375-R1 cell lines treated with CB839 for 72 hours in vitro. Data is representative of triplicates and S.D. (G) Kaplan-Meier analysis of OS for mice bearing intracranial A375-R1 xenografts treated with vehicle or CB839 (200 mg/kg p.o. twice daily). Significance was determined by log-rank testing. (H) Kaplan-Meier analysis of OS for mice bearing intracranial MEL624 xenografts treated with vehicle or CB839 (200 mg/kg p.o. twice daily). Significance determined by log-rank testing.
Figure 4. Oxidative phosphorylation associates with immunosuppression in melanoma brain metastases. (A) CIBERSORT analysis of High-OXPHOS (n=21) and Low-OXPHOS (n=25) MBMs. Data are presented as a heatmap of median-centered log2-tranformed estimates of the 22 immune cell populations listed on the right side of the heatmap. FDR q-values are listed to the left of the graph along with determination of significance (FDR q-val < 0.05). No immune cell population significantly differed between the groups. (B-D) IHC analysis for CD3, CD8, and PAX5 positive cells in High- and Low-OXPHOS MBMs. H-scores shown, as described in Figure 1. (E-F) Comparison of a 6-gene IFN-γ mRNA signature and 18-gene T-cell inflamed gene expression profile (GEP) for High- versus Low-OXPHOS MBMs. (B-F) Lines represent mean ± S.D., and each dot represents a single tumor. Significance determined by two-sided Student’s t-test.

Figure 5. Metformin improves the response of High-OXPHOS, syngeneic intracranial melanoma xenografts to anti-PD1 immunotherapy. B16-F10 cells were implanted intracranially in C57BL/6 mice and treated for 96 hours with low-dose metformin (50 mg/kg i.p. every other day; n=3) or PBS (n=4). qRT-PCR analysis was used to assess mRNA levels of (A) panel of genes previously shown to correlate with the presence of activated CD8+ T cells in melanomas, and (B) panel of IFNγ-related genes previously shown to predict response to anti-PD1 in metastatic melanoma patients. Values represent mean ± S.D. ****p < 0.0001; ***p < 0.001; **p < 0.01, *p < 0.05 by two-sided Student’s t-test. (C) Kaplan-Meier analysis of OS for C57BL/6 mice bearing intracranial B16-F10 xenografts treated with isotype antibody control (200 µg i.p. 3x/week) + PBS (10 µl/g body weight i.p. every other day) (Group 1; n=5); anti-PD1 (200 µg i.p. 3x/week) + PBS (10 µl/g body weight i.p. every other day) (Group 2; n=7); isotype control (200 µg i.p. 3x/week) + metformin (50 mg/kg i.p. every other day) (Group 3; n=6); and anti-PD1 (200 µg i.p. 3x/week) + metformin (50 mg/kg i.p. every other day) (Group 4; n=7). Significance of differences determined by log-rank testing.
Figure 1

A

B

High vs. Low

C

Overall Survival (%) vs. Months Since Accession

D

Age

E

Gender

F

BMI

G

Previous XRT

- KEGG Oxidative Phosphorylation
- MOOATHA VOXPHOS
- Reactome ETC Chemosensitivity ATP Synthesis
- KEGG Citrate Cycle/TCA Cycle
- Reactome Citric Acid Cycle/TCA Cycle
- MOOATHA TCA
- Hallmarks OXPHOS Phosphorylation
- Reactome TCA Cycle and Respiratory ETC

NES = 8.91
FDR q-val < 0.0001

HR = 0.3934 (95% CI, 0.1865 - 0.8267)
p = 0.0143

p = 0.0661

p = 0.1328

p = 0.2347

p = 0.2122
Figure 2

A

Log2-CPM

PGC1α

MITF

High-OXPHOS (n=21)

Low-OXPHOS (n=21)

p adj = 0.019

p adj = 0.017

B

MSigDB: Hallmarks

MYC_TARGETS_VI

OXIDATIVE_PHOSPHORYLATION

E2F_TARGETS

MTORC1_SIGNALING

G2M_CHECKPOINT

ADIPGENESIS

DNA_REPAIR

UNFOLDED_PROTEIN_RESPONSE

GLYCOLYSIS

HEME_METABOLISM

ALLOGRAFT_REJECTION

INTERFERON_GAMMA_RESPONSE

INTERFERON_ALPHA_RESPONSE

NES

C

Frequency of PTEN Loss (%)

8/15

5/12

High-OXPHOS

Low-OXPHOS

p = 0.7756

D

P-PRAS40

High-OXPHOS (n=16)

Low-OXPHOS (n=16)

p = 0.4339

E

P-S6

High-OXPHOS (n=16)

Low-OXPHOS (n=15)

p = 0.0027

F

High-OXPHOS

Low-OXPHOS

P-S6
Figure 5

A

Fold Change vs. Vehicle

PBS (n=4)  Metformin (n=3)

CD6a  Gzmb  Ifnγ  Prf1  Tnfα

B

Fold Change vs. Vehicle

PBS (n=4)  Metformin (n=3)

Ido1  Cxcl10  Cxcl9  Stat1  Ifnγ

C

B16-F10

Overall Survival (%)

Days Post Treatment Initiation

1. Isotype Ctrl + PBS (n=5)
2. Anti-PD1 + PBS (n=7)
3. Isotype Ctrl + Metformin (n=6)
4. Anti-PD1 + Metformin (n=7)

| Group | Median OS | P vs. Group #1 | P vs. Group #2 | P vs. Group #3 |
|-------|-----------|----------------|----------------|----------------|
| 1     | 10        |                |                |                |
| 2     | 11        | 0.4361         |                |                |
| 3     | 12        | 0.4533         |                |                |
| 4     | 18        | 0.0127         | 0.1972         | 0.0262         |